The Reason Why Takeda Pharmaceutical Co. Ltd. May Pay MacroGenics, Inc. Up To $1.6 Billion For Four Molecules That Don't Yet Exist

MacroGenics Inc. this week announced its sixth collaboration surrounding its core platform, a pact with Takeda Pharmaceutical Co. to jointly develop and commercialize as many as four drugs. The deal could end up yielding the Rockville biotech $400 million each in milestone payments, plus potential royalties.

The high-dollar deal is notable for another reason: It centers on four molecules that don't yet exist.

Help employers find you! Check out all the jobs and post your resume.

Back to news